Our findings align with prior evidence of AKT phosphorylation activation in CSLCs (17, 18), confirming the capacity of alisertib to inhibit AURKA–AKT and reduce HCC-TRC stemness. Here, AKT1 is linked to hepatocellular carcinoma.